Safety Study of SGN-CD70A in Cancer Patients

Seagen

Status and phase

Completed

Phase 1

Conditions

Diffuse, Large B-Cell, Lymphoma

Follicular Lymphoma, Grade 3

Renal Cell Carcinoma

Mantle-Cell Lymphoma

Treatments

Drug: SGN-CD70A

Study type

Interventional

Funder types

Industry

Identifiers

NCT02216890

SGN70A-001

Details and patient eligibility

About

This study will examine the safety profile of SGN-CD70A. The study will test increasing doses of SGN-CD70A given every 3 weeks (or an alternate dosing schedule up to every 6 weeks) to small groups of patients. The goal is to find the highest dose of SGN-CD70A that can be given to patients without causing unacceptable side effects. The pharmacokinetics and antitumor activity of SGN-CD70A will also be evaluated.

Enrollment

38 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Metastatic renal cell carcinoma, mantle cell lymphoma, or diffuse large B-cell lymphoma including Grade 3b follicular lymphoma
Relapsed, refractory, or progressive disease following at least 2 prior systemic therapies
Confirmed positive CD70 expression on tumor tissue
Eastern Cooperative Oncology Group performance status 0 or 1
Adequate baseline hematologic, pulmonary, renal, and hepatic function
Measurable disease

Exclusion criteria

Prior treatment with anti-CD70 directed therapy unless CD70 expression is confirmed on tumor tissue obtained after the treatment
Patients <100 days since prior allogeneic stem cell transplant
Less than 4 weeks since prior treatment; or 2 weeks if patient experienced disease progression on the prior treatment